Horizon Pharma plc (NASDAQ:HZNP) Sale Analysis


Quarterly Sales and EPS Roundup:

Horizon Pharma plc (HZNP) reported sales (ttm) of 1.03 Billion, whereas, 9 number of analysts estimated the mean sale of 259.42 million. The analysts estimated sales for the higher end at 293.7 million and lower end at 237.3 million while the year ago reported sale was 326.56 million.

9 number of analysts have estimated the sales of the company for the quarter ending Oct 16, 2017- Oct 20, 2017, analysts estimated mean sale target of 263.63 million while high and low sale targets are estimated at 301.7 million and 229.4 million respectively.

Horizon Pharma plc (HZNP) reported earning per shares for the quarter ending Aug 07 BMO at 0.41, whereas, 11 number of analysts estimated the mean EPS at 0.23. The analysts estimated EPS for the higher end at 0.28 and lower end at 0.16 while the year ago reported earnings per share was 0.69.

The company has mean EPS estimate of 0.23 reported by 11 number of analyst for the quarter ending Current Qtr.(Sep2017). The analysts estimated mean EPS at 0.23 while the high and low EPS estimate stand at 0.3 and 0.08 respectively. In contrast to the year ago quarter EPS was at 0.79.

Valuation Ratios of Horizon Pharma plc (HZNP) versus the Industry and Sector:

Let’s have a look at some of the important valuation ratios of the Horizon Pharma plc (HZNP). These ratios are important while doing valuation of the company or the shares of the company.

Horizon Pharma plc (HZNP) currently has the company’s industry has 12.4 P/E and the sector P/E is 15.81. The industry’s and sector’s  high P/E for the past year is 136.39 and 33.45 respectively and low P/E ratio for the last 5 years is 5.63 for the industry and 9.99 for the Sector.

Beta is also an important valuation ratio for analyzing the stock of the company, HZNP has its industry and Sector’s beta remains at 0.86 and 0.78 respectively.

5 Year Growth Rate Analysis:

Growth rates are very important while analyzing the long term growth and valuation of a certain company.

5 year sales growth rate is an important factor for valuation analysis, the industry’s and the sector’s growth for next 5 years ticked at -3.13 and -8.33 respectively.

Horizon Pharma plc (HZNP) Trading Statistics:

The company declined -3.3% and closed its last trading session at $12.71. The market capitalization of the company is at $2 Billion. The stock touched 52-week High of $21.98 on 11/28/16 and 52-week Low of $9.45 on 05/10/17. The stock currently has Weekly Volatility of 4.95% and Monthly Volatility of 4.24%. The Beta for the company stands at 1.52 and its Average True Range (ATR) shows a value of 0.59.